BAYN:F-Bayer Aktiengesellschaft (EUR)

COMMON STOCK | Drug Manufacturers-General | F

Last Closing Price

EUR 48.72

Change

+0.24 (+0.48)%

Market Cap

EUR 47.65B

Volume

0.01M

Average Target Price

EUR 70.37 (+44.43%)
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict

About

Bayer Aktiengesellschaft operates as a life science company worldwide. It operates through Pharmaceuticals, Consumer Health, and Crop Science segments. The Pharmaceuticals segment offers prescription products primarily for cardiology and women's health care; specialty therapeutics in the areas of oncology, hematology, and ophthalmology; and diagnostic imaging equipment and contrast agents. The Consumer Health segment markets nonprescription over-the-counter medicines, medical products, medicated skincare products, and self-care solutions in the dermatology, nutritional supplements, pain and cardiovascular risk prevention, digestive health, allergy, and cold and cough. The Crop Science segment offers chemical and biological crop protection products, improved plant traits, seeds, digital solution, and pest and weed control products, as well as customer service for agriculture. This segment also provides breeding, propagation, and production/processing of seeds, including seed dressing. Bayer Aktiengesellschaft has a collaboration agreement with MD Anderson Cancer Center at the University of Texas to develop cancer treatments; and research collaboration agreements with Haplogen GmbH and Kyoto University to identify new drugs candidates for the treatment of pulmonary diseases. The company distributes its products through wholesalers, pharmacies, supermarket and drugstore chains, online and other retailers, and hospitals, as well as directly to farmers. It has strategic research alliance with Kyoto University, Sensyne Health plc, and Atomwise Inc. Bayer Aktiengesellschaft was founded in 1863 and is based in Leverkusen, Germany. Address: Kaiser-Wilhelm-Allee 1, Leverkusen, Germany, 51368

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2020-12-01 )

Largest Industry Peers for Drug Manufacturers-General

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
JNJ:F Johnson & Johnson

+2.92 (+2.43%)

EUR325.90B 19.36 12.53
BRM:F Bristol-Myers Squibb Company

+0.73 (+1.41%)

EUR119.46B 94.49 10.22
SNW:F Sanofi

-0.63 (-0.74%)

EUR105.58B 9.44 6.50
CUP:F Chugai Pharmaceutical Co., Ltd

-0.20 (-0.51%)

EUR66.16B 27.69 0.22
GIS:F Gilead Sciences, Inc

+1.06 (+2.11%)

EUR64.87B 50.95 16.28
IDP:F Biogen Inc

+2.50 (+1.25%)

EUR31.26B 6.68 4.89
CVG:F CSPC Pharmaceutical Group Limi..

N/A

EUR9.78B 11.84 1.90
OFK:F Orion Oyj

-0.86 (-2.16%)

EUR5.42B 22.84 18.04
SZD:F Santen Pharmaceutical Co., Ltd

-0.40 (-2.94%)

EUR5.40B 17.25 0.10
UNJ:F The United Laboratories Intern..

+0.01 (+0.83%)

EUR1.16B 100.83 0.75

ETFs Containing BAYN

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Drug Manufacturers-General)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -33.27% 9% F 15% F
Dividend Return 3.84% 55% F 59% F
Total Return -29.43% 8% F 16% F
Trailing 12 Months  
Capital Gain -28.30% 8% F 18% F
Dividend Return 4.12% 55% F 59% F
Total Return -24.18% 8% F 18% F
Trailing 5 Years  
Capital Gain -58.11% 17% F 16% F
Dividend Return 11.69% 18% F 28% F
Total Return -46.41% 8% F 15% F
Average Annual (5 Year Horizon)  
Capital Gain -8.37% N/A N/A 17% F
Dividend Return 3.12% N/A N/A 40% F
Total Return -5.25% N/A N/A 15% F
Risk Return Profile  
Volatility (Standard Deviation) 22.12% N/A N/A 65% D
Risk Adjusted Return -23.73% N/A N/A 14% F
Market Capitalization 47.65B 58% F 96% A
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Drug Manufacturers-General)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 22.68 50% F 37% F
Price/Book Ratio 1.56 83% B 54% F
Price / Cash Flow Ratio 5.81 50% F 38% F
EV/EBITDA 8.55 42% F 47% F
Management Effectiveness  
Return on Equity -41.12% 10% F 10% F
Return on Invested Capital 4.77% 8% F 46% F
Return on Assets -7.35% 8% F 12% F
Debt to Equity Ratio 75.96% 33% F 32% F
Technical Ratios  
Short Ratio N/A N/A N/A N/A N/A
Short Percent N/A N/A N/A N/A N/A
Beta 1.36 8% F 29% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (EUR)

Quarterly Financials (EUR)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Underpriced compared to book value

The stock is trading low compared to its peers on a price to book value basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

What to not like:
Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Poor capital utilization

The company management has delivered below median return on invested capital in the most recent 4 quarters compared to its peers.

Higly leveraged

The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Low Revenue Growth

This stock has shown below median revenue growth in the previous 5 years compared to its sector